Physician profile
Andrew Schiff
NPI 1801254248
$4,204.30
in general payments reported to CMS, 2019-2025
29 companies · $2,309 in 2025
The $2,309 reported for 2025 was more than what 88% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.99 · 2020: $176 · 2021: $17.05 · 2022: $43.92 · 2023: $243 · 2024: $1,315 · 2025: $2,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,866.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,190.99 | 2020-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $629.29 | 2020-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $362.45 | 2023-2025 | Dupixent |
| Genzyme Corporation | $248.38 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.26 | 2020-2025 | Ofev, Jascayd |
| Insmed, INC. | $158.33 | 2020-2025 | Arikayce, Brinsupri |
| Ani Pharmaceuticals, INC. | $146.77 | 2025 | Purified Cortrophin Gel |
| Jazz Pharmaceuticals INC. | $135.83 | 2024-2025 | |
| Genentech USA, INC. | $133.13 | 2019-2025 | Xolair |
| Amgen INC. | $132.97 | 2023-2025 | Tezspire |
| Philips North America LLC | $131.71 | 2020-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Actelion Pharmaceuticals US, INC. | $114.29 | 2024-2025 | Uptravi, Opsumit |
| Takeda Pharmaceuticals U.S.A., INC. | $112.19 | 2024-2025 | Aralast |
| Verona Pharma, INC. | $93.97 | 2025 | Ohtuvayre |
| Harmony Biosciences LLC | $71.98 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $70.76 | 2022-2025 | |
| Mylan Specialty L.P. | $49.01 | 2024 | Yupelri |
| Avadel Cns Pharmaceuticals, LLC | $30.54 | 2024 | Lumryz |
| Vapotherm INC | $26.67 | 2024 | Vapotherm |
| Grifols USA, LLC | $20.13 | 2025 | Prolastin-C Liquid |
| United Therapeutics Corporation | $19.06 | 2025 | Tyvaso |
| 3b Medical, INC. | $18.26 | 2024 | Luna |
| Pfizer INC. | $17.19 | 2024 | |
| Nabriva Therapeutics, Plc | $17.11 | 2020 | |
| Csl Behring | $17.05 | 2021 | |
| Lilly USA, LLC | $16.39 | 2025 | Zepbound |
| Axsome Therapeutics, INC. | $16.06 | 2023 | Sunosi |
| Paratek Pharmaceuticals, INC. | $15.73 | 2024 | Nuzyra |
| Viatris Specialty LLC | $14.80 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Schiff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.